Translating genome-wide association findings into new therapeutics for psychiatry

Gerome Breen, Qingqin Li, Bryan L. Roth, Patricio O'Donnell, Michael Didriksen, Ricardo Dolmetsch, Paul F. O'Reilly, Héléna A. Gaspar, Husseini Manji, Christopher Huebel, John R. Kelsoe, Dheeraj Malhotra, Alessandro Bertolino, Danielle Posthuma, Pamela Sklar, Shitij Kapur, Patrick F. Sullivan, David A. Collier, Howard Edenberg

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

Original languageEnglish (US)
Pages (from-to)1392-1396
Number of pages5
JournalNature Neuroscience
Volume19
Issue number11
DOIs
StatePublished - Oct 26 2016

Fingerprint

Psychiatry
Genome
Genome-Wide Association Study
Genomics
Sample Size
Therapeutics
Motivation
Differential Diagnosis
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Breen, G., Li, Q., Roth, B. L., O'Donnell, P., Didriksen, M., Dolmetsch, R., ... Edenberg, H. (2016). Translating genome-wide association findings into new therapeutics for psychiatry. Nature Neuroscience, 19(11), 1392-1396. https://doi.org/10.1038/nn.4411

Translating genome-wide association findings into new therapeutics for psychiatry. / Breen, Gerome; Li, Qingqin; Roth, Bryan L.; O'Donnell, Patricio; Didriksen, Michael; Dolmetsch, Ricardo; O'Reilly, Paul F.; Gaspar, Héléna A.; Manji, Husseini; Huebel, Christopher; Kelsoe, John R.; Malhotra, Dheeraj; Bertolino, Alessandro; Posthuma, Danielle; Sklar, Pamela; Kapur, Shitij; Sullivan, Patrick F.; Collier, David A.; Edenberg, Howard.

In: Nature Neuroscience, Vol. 19, No. 11, 26.10.2016, p. 1392-1396.

Research output: Contribution to journalReview article

Breen, G, Li, Q, Roth, BL, O'Donnell, P, Didriksen, M, Dolmetsch, R, O'Reilly, PF, Gaspar, HA, Manji, H, Huebel, C, Kelsoe, JR, Malhotra, D, Bertolino, A, Posthuma, D, Sklar, P, Kapur, S, Sullivan, PF, Collier, DA & Edenberg, H 2016, 'Translating genome-wide association findings into new therapeutics for psychiatry', Nature Neuroscience, vol. 19, no. 11, pp. 1392-1396. https://doi.org/10.1038/nn.4411
Breen G, Li Q, Roth BL, O'Donnell P, Didriksen M, Dolmetsch R et al. Translating genome-wide association findings into new therapeutics for psychiatry. Nature Neuroscience. 2016 Oct 26;19(11):1392-1396. https://doi.org/10.1038/nn.4411
Breen, Gerome ; Li, Qingqin ; Roth, Bryan L. ; O'Donnell, Patricio ; Didriksen, Michael ; Dolmetsch, Ricardo ; O'Reilly, Paul F. ; Gaspar, Héléna A. ; Manji, Husseini ; Huebel, Christopher ; Kelsoe, John R. ; Malhotra, Dheeraj ; Bertolino, Alessandro ; Posthuma, Danielle ; Sklar, Pamela ; Kapur, Shitij ; Sullivan, Patrick F. ; Collier, David A. ; Edenberg, Howard. / Translating genome-wide association findings into new therapeutics for psychiatry. In: Nature Neuroscience. 2016 ; Vol. 19, No. 11. pp. 1392-1396.
@article{07a964b0b4c5449fa56f92bc7ca928be,
title = "Translating genome-wide association findings into new therapeutics for psychiatry",
abstract = "Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.",
author = "Gerome Breen and Qingqin Li and Roth, {Bryan L.} and Patricio O'Donnell and Michael Didriksen and Ricardo Dolmetsch and O'Reilly, {Paul F.} and Gaspar, {H{\'e}l{\'e}na A.} and Husseini Manji and Christopher Huebel and Kelsoe, {John R.} and Dheeraj Malhotra and Alessandro Bertolino and Danielle Posthuma and Pamela Sklar and Shitij Kapur and Sullivan, {Patrick F.} and Collier, {David A.} and Howard Edenberg",
year = "2016",
month = "10",
day = "26",
doi = "10.1038/nn.4411",
language = "English (US)",
volume = "19",
pages = "1392--1396",
journal = "Nature Neuroscience",
issn = "1097-6256",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Translating genome-wide association findings into new therapeutics for psychiatry

AU - Breen, Gerome

AU - Li, Qingqin

AU - Roth, Bryan L.

AU - O'Donnell, Patricio

AU - Didriksen, Michael

AU - Dolmetsch, Ricardo

AU - O'Reilly, Paul F.

AU - Gaspar, Héléna A.

AU - Manji, Husseini

AU - Huebel, Christopher

AU - Kelsoe, John R.

AU - Malhotra, Dheeraj

AU - Bertolino, Alessandro

AU - Posthuma, Danielle

AU - Sklar, Pamela

AU - Kapur, Shitij

AU - Sullivan, Patrick F.

AU - Collier, David A.

AU - Edenberg, Howard

PY - 2016/10/26

Y1 - 2016/10/26

N2 - Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

AB - Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84994079504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994079504&partnerID=8YFLogxK

U2 - 10.1038/nn.4411

DO - 10.1038/nn.4411

M3 - Review article

C2 - 27786187

AN - SCOPUS:84994079504

VL - 19

SP - 1392

EP - 1396

JO - Nature Neuroscience

JF - Nature Neuroscience

SN - 1097-6256

IS - 11

ER -